Efficacy and Challenges of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from the Alliance A021202 Trial
Highlight
– Pazopanib significantly improved progression-free survival (PFS) compared to placebo in advanced extrapancreatic neuroendocrine tumors (epNETs).
– The majority of patients had midgut primary tumors and prior somatostatin analog (SSA) treatment.
– Despite PFS benefit, pazopanib was associated with higher rates of severe adverse events including grade 5 deaths.
– No significant overall survival benefit was observed, leading to the decision not to pursue further development of pazopanib in this indication.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.